202 related articles for article (PubMed ID: 28401495)
1. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis.
Martín-Merino E; Huerta-Álvarez C; Prieto-Alhambra D; Montero-Corominas D
Arch Osteoporos; 2017 Dec; 12(1):39. PubMed ID: 28401495
[TBL] [Abstract][Full Text] [Related]
2. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
[TBL] [Abstract][Full Text] [Related]
3. Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK.
Martín-Merino E; Petersen I; Hawley S; Álvarez-Gutierrez A; Khalid S; Llorente-Garcia A; Delmestri A; Javaid MK; Van Staa TP; Judge A; Cooper C; Prieto-Alhambra D
Osteoporos Int; 2018 Feb; 29(2):467-478. PubMed ID: 29199359
[TBL] [Abstract][Full Text] [Related]
4. Secular trends of use of anti-osteoporotic treatments in Spain: A population-based cohort study including over 1.5million people and more than 12years of follow-up.
Martín-Merino E; Huerta-Álvarez C; Prieto-Alhambra D; Álvarez-Gutiérrez A; Montero-Corominas D
Bone; 2017 Dec; 105():292-298. PubMed ID: 28890137
[TBL] [Abstract][Full Text] [Related]
5. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan.
Lin SY; Chen YM; Chen WJ; Li CY; Ku CK; Chen CH; Chien LN
Arch Osteoporos; 2022 Jul; 17(1):94. PubMed ID: 35840845
[TBL] [Abstract][Full Text] [Related]
7. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
8. Drug utilization analysis of osteoporosis medications in seven European electronic health databases.
Tan EH; Robinson DE; Jödicke AM; Mosseveld M; Bødkergaard K; Reyes C; Moayyeri A; Voss A; Marconi E; Lapi F; Reinold J; Verhamme KMC; Pedersen L; Braitmaier M; de Wilde M; Ruiz MF; Aragón M; Bosco-Levy P; Lassalle R; Prieto-Alhambra D; Sanchez-Santos MT
Osteoporos Int; 2023 Oct; 34(10):1771-1781. PubMed ID: 37436441
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
Inderjeeth CA; Foo AC; Lai MM; Glendenning P
Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
Bone; 2023 Jan; 166():116605. PubMed ID: 36347433
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
Pedersen AB; Heide-Jørgensen U; Sørensen HT; Prieto-Alhambra D; Ehrenstein V
JAMA Netw Open; 2019 Apr; 2(4):e192416. PubMed ID: 31002319
[TBL] [Abstract][Full Text] [Related]
12. Treatment of primary osteoporosis in men.
Giusti A; Bianchi G
Clin Interv Aging; 2015; 10():105-15. PubMed ID: 25565793
[TBL] [Abstract][Full Text] [Related]
13. Trends in postmenopausal osteoporosis treatment in France during the period 2007-2016: A nationwide claims database analysis.
Cortet B; Schott AM; Désaméricq G; Chauny JV; Samama P; Emery C; Fagnani F
Bone; 2022 Jan; 154():116255. PubMed ID: 34763115
[TBL] [Abstract][Full Text] [Related]
14. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis.
Overman RA; Gourlay ML; Deal CL; Farley JF; Brookhart MA; Layton JB
Osteoporos Int; 2015 May; 26(5):1515-24. PubMed ID: 25600474
[TBL] [Abstract][Full Text] [Related]
15. Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis.
Usui T; Funagoshi M; Seto K; Ide K; Tanaka S; Kawakami K
Arch Osteoporos; 2018 May; 13(1):54. PubMed ID: 29725863
[TBL] [Abstract][Full Text] [Related]
16. Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis.
Zarowitz BJ; Cheng LI; Allen C; O'Shea T; Stolshek B
J Am Med Dir Assoc; 2015 Apr; 16(4):341-8. PubMed ID: 25726417
[TBL] [Abstract][Full Text] [Related]
17. Early (1-year) Discontinuation of Different Anti-osteoporosis Medications Compared: A Population-Based Cohort Study.
Carbonell-Abella C; Pages-Castella A; Javaid MK; Nogues X; Farmer AJ; Cooper C; Diez-Perez A; Prieto-Alhambra D
Calcif Tissue Int; 2015 Dec; 97(6):535-41. PubMed ID: 26202819
[TBL] [Abstract][Full Text] [Related]
18. Anti-osteoporosis medication treatment pattern after osteoporotic fracture during 2010-2016 in Fujian, China.
Wang X; Li C; He Y; Wang T; Zhang H; Ma Z; Ma H; Zhao H
Arch Osteoporos; 2020 Aug; 15(1):134. PubMed ID: 32820451
[TBL] [Abstract][Full Text] [Related]
19. Persistence with oral bisphosphonates and denosumab among older adults in primary care in Ireland.
Walsh ME; Fahey T; Moriarty F
Arch Osteoporos; 2021 Apr; 16(1):71. PubMed ID: 33864529
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
